凯因科技（688687）：利润持续增长，期待派益生顺利获批

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 47.33 RMB [7][5]. Core Views - The company reported a revenue of 570 million RMB for the first half of 2025, a decrease of 5% year-on-year, while the net profit attributable to the parent company was 50 million RMB, an increase of 12% year-on-year. The second quarter revenue was 330 million RMB, down 13% year-on-year, with a net profit of 20 million RMB, up 7% year-on-year. The company is expected to receive approval for its long-acting interferon product, Paiyisheng, within 2025, which is anticipated to strengthen its position in the domestic hepatitis market [1][5]. Summary by Sections Financial Performance - The company achieved a revenue of 570 million RMB in H1 2025, down 5% year-on-year, and a net profit of 50 million RMB, up 12% year-on-year. In Q2 2025, revenue was 330 million RMB, down 13% year-on-year, with a net profit of 20 million RMB, up 7% year-on-year [1]. Product Development - The company is focusing on functional cures for hepatitis B, with KW-040 approved for clinical trials in July 2025. The long-acting interferon has a new indication for adult chronic hepatitis B, which is expected to be approved within 2025 and enter the medical insurance negotiation in 2026 [3][4]. Research and Development - The company increased its R&D investment to 71.41 million RMB in H1 2025, accounting for 12.6% of revenue, up 0.8 percentage points year-on-year. The company is also expanding its product pipeline in the field of immune diseases [4]. Profit Forecast Adjustments - The profit forecast for 2025-2027 has been adjusted, with expected revenues of 1.28 billion RMB, 1.50 billion RMB, and 1.69 billion RMB, representing a decrease of 7%, 7%, and 8% from previous estimates. The net profits are expected to be 170 million RMB, 210 million RMB, and 240 million RMB, with adjustments of -1%, -1%, and -9% respectively [12][5]. Valuation - Using the SOTP valuation method, the company's reasonable valuation is estimated at 8.09 billion RMB, with a target price of 47.33 RMB per share [13][5].